On Jun. 10, 2020, Catalent announced that it had signed an agreement with Spicona to develop a virus-like protein (VLP)-based vaccine against COVID-19. Under the terms of the agreement, Catalent will use its proprietary GPEx cell line development technology to develop a cell line expressing the recombinant VLP at its Madison, Wisconsin facility.